• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Gain Therapeutics Inc (NQ: GANX )

    1.640 -0.140 (-7.87%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Oct 1, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 400,891
    Open 1.810
    Bid (Size) 1.520 (20)
    Ask (Size) 1.880 (1)
    Prev. Close 1.780
    Today's Range 1.541 - 1.810
    52wk Range 0.8900 - 5.330
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Gain Therapeutics Presents Phase 1 GT-02287 Data at International Congress of Parkinson’s Disease and Movement Disorders Demonstrating Increase in GCase Activity in Healthy Volunteers
    From Gain Therapeutics, Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Friday's After-Market Session
    Via Benzinga

    Performance

    YTD
    -54.76%
    -54.76%
    1 Month
    +57.69%
    +57.69%
    3 Month
    +37.24%
    +37.24%
    6 Month
    -57.84%
    -57.84%
    1 Year
    -49.85%
    -49.85%

    More News

    Read More
    Gain Therapeutics To Host Virtual Webinar on Results From Phase 1 Study and Design of Upcoming Phase 1b Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for Parkinson’s Disease
    From Gain Therapeutics, Inc.
    Via GlobeNewswire
    Gain Therapeutics to Present Preclinical GT-02287 Data in Parkinson’s Disease Models Including Two Late-Breakers at Neuroscience 2024
    From Gain Therapeutics, Inc.
    Via GlobeNewswire
    Gain Therapeutics to Participate at H.C. Wainwright 26th Annual Global Investment Conference
    From Gain Therapeutics, Inc.
    Via GlobeNewswire
    Small-Cap Gain Therapeutics Stock Falls On Phase 1 Data From Its Lead Asset For Parkinson's Disease
    Via Benzinga
    Gain Therapeutics Announces Positive Topline Results from the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for Parkinson’s Disease
    From Gain Therapeutics, Inc.
    Via GlobeNewswire
    GANX Stock Earnings: Gain Therapeutics Misses EPS for Q2 2024
    Via InvestorPlace
    Gain Therapeutics Reports Financial Results for Second Quarter 2024 and Provides Corporate Update
    From Gain Therapeutics, Inc.
    Via GlobeNewswire
    Gain Therapeutics to Participate at BTIG Virtual Biotechnology Conference
    From Gain Therapeutics, Inc.
    Via GlobeNewswire
    7 Sorry Biotech Stocks Set to Make Investors Sad
    Via InvestorPlace
    12 Health Care Stocks Moving In Thursday's Pre-Market Session
    Via Benzinga
    Gain Therapeutics to Hold a Business Update Conference Call on July 1, 2024
    From Gain Therapeutics, Inc.
    Via GlobeNewswire
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
    Via InvestorPlace
    Gain Therapeutics, Inc. Appoints Gene Mack as Interim CEO
    From Gain Therapeutics, Inc.
    Via GlobeNewswire
    Gain Therapeutics Presents GT-02287 Data at Federation of European Neuroscience Societies (FENS) Forum 2024 Demonstrating Improvements in Cognitive Performance in a Preclinical Model of GBA1 Parkinson’s disease
    From Gain Therapeutics, Inc.
    Via GlobeNewswire
    Gain Therapeutics to Participate at H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
    From Gain Therapeutics, Inc.
    Via GlobeNewswire
    InvestorNewsBreaks – Gain Therapeutics Inc. (NASDAQ: GANX) Releases Pricing of Underwritten Public Offering, Projected to Reach $11M
    Via Investor Brand Network
    Topics Artificial Intelligence
    Exposures Artificial Intelligence
    S&P 500 Edges Lower; RH Shares Plunge After Q1 Results
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Why AMMO Shares Are Trading Lower By Over 19%? Here Are Other Stocks Moving In Friday's Mid-Day Session
    Via Benzinga
    12 Health Care Stocks Moving In Friday's Intraday Session
    Via Benzinga
    Gold Gains 1%; US Consumer Sentiment Falls In June
    Via Benzinga
    Dear ARM Stock Fans, Mark Your Calendars for June 24
    Via InvestorPlace
    Dow Tumbles Over 200 Points; Adobe Earnings Top Views
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Why Is Gain Therapeutics (GANX) Stock Down 25% Today?
    Via InvestorPlace
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.